ERBB2 and breast carcinoma: Among HR-positive/HER2-negative breast cancer, 5-year overall survival (OS) and breast cancer-specific survival exceed 95% in T1a and T1b tumors, and invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) exceed 90%, regardless of adjuvant chemotherapy.